Privately-held clinical-stage immunotherapy company, Vaccinex, Inc., recently announced that it has signed a multi-target antibody discovery deal with Five Prime Therapeutics. Vaccinex said that it has entered into a multi-target collaboration agreement with Five Prime to utilize Vaccinex’s ActivMab antibody discovery platform for the discovery of monoclonal antibodies against novel …